Literature DB >> 14556660

Estrogen sulfotransferase and sulfatase: Roles in the regulation of estrogen activity in human uterine endometrial carcinomas.

Kyoko Tanaka1, Kaneyuki Kubushiro, Yuriko Iwamori, Yuzuru Okairi, Kazushige Kiguchi, Isamu Ishiwata, Katsumi Tsukazaki, Shiro Nozawa, Masao Iwamori.   

Abstract

The regulation of estrogen activity through the formation and cleavage of sulfoconjugates of estrogens is known to be related to the progression and metastasis of estrogen-dependent breast carcinomas, but the involvement of sulfoconjugates in the steroid stimulation of endometrial functions and the progression of endometrial adenocarcinomas is not clearly understood yet. Estrogen sulfotransferase (EST) in the uterine endometria during the follicular phase was more active than during the luteal phase, but estrogen sulfate (ES) sulfatase exhibited lower activity during the follicular phase than during the luteal phase. However, ES sulfatase activities in cancerous tissues were lower than those in normal endometria and endometrial adenocarcinoma-derived cells, among which the activity was exceedingly high in Ishikawa cells, suggesting that ES sulfatase in Ishikawa cells contributes to the estrogen-dependent growth of these cells. EST activities higher than that in Ishikawa cells were found in only 3 of 24 cancerous tissues. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of the EST and ES sulfatase genes in carcinoma-derived cells demonstrated the extensive expression of both genes in Ishikawa cells. The isolated EST gene was transfected into Ishikawa cells with a mammalian expression vector to establish cell clones with enhanced EST activity, and the estrogen-dependent cell growth of the resultant cell clones was found to be abolished, due to the enhanced sulfoconjugation of estrogen. Since ES sulfatase activity in cancerous tissues was significantly lower than that in Ishikawa cells, it might be not involved in the enhancement of estrogen activity associated with the pathogenesis of endometrial adenocarcinoma tissues.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14556660     DOI: 10.1111/j.1349-7006.2003.tb01369.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  6 in total

1.  Interrogating the druggable genome with structural informatics.

Authors:  Kevin Hambly; Joseph Danzer; Steven Muskal; Derek A Debe
Journal:  Mol Divers       Date:  2006-09-22       Impact factor: 2.943

2.  Expression of α2,6-sialic acid-containing and Lewis-active glycolipids in several types of human ovarian carcinomas.

Authors:  Kyoko Tanaka; Mikio Mikami; Daisuke Aoki; Kazushige Kiguchi; Isamu Ishiwata; Masao Iwamori
Journal:  Oncol Lett       Date:  2010-09-09       Impact factor: 2.967

3.  Biological activity of oestradiol sulphate in an oviparous amniote: implications for maternal steroid effects.

Authors:  Ryan T Paitz; Rachel M Bowden
Journal:  Proc Biol Sci       Date:  2010-11-24       Impact factor: 5.349

Review 4.  Intracrine Regulation of Estrogen and Other Sex Steroid Levels in Endometrium and Non-gynecological Tissues; Pathology, Physiology, and Drug Discovery.

Authors:  Gonda Konings; Linda Brentjens; Bert Delvoux; Tero Linnanen; Karlijn Cornel; Pasi Koskimies; Marlies Bongers; Roy Kruitwagen; Sofia Xanthoulea; Andrea Romano
Journal:  Front Pharmacol       Date:  2018-09-19       Impact factor: 5.810

Review 5.  The Important Roles of Steroid Sulfatase and Sulfotransferases in Gynecological Diseases.

Authors:  Tea Lanišnik Rižner
Journal:  Front Pharmacol       Date:  2016-02-18       Impact factor: 5.810

6.  Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancer.

Authors:  Felicitas Mungenast; Stefanie Aust; Ignace Vergote; Adriaan Vanderstichele; Jalid Sehouli; Elena Braicu; Sven Mahner; Dan Cacsire Castillo-Tong; Robert Zeillinger; Theresia Thalhammer
Journal:  Oncol Lett       Date:  2017-04-03       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.